RXRX
Recursion Pharmaceuticals Inc
$
5.520
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
5.7356
Open
5.700
VWAP
5.54
Vol
43.30M
Mkt Cap
2.40B
Low
5.410
Amount
239.91M
EV/EBITDA(TTM)
--
Total Shares
237.66M
EV
1.89B
EV/OCF(TTM)
--
P/S(TTM)
30.75
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
16.64M
+12.85%
-0.350
-30%
21.70M
+377.34%
-0.327
-38.28%
19.36M
-25.77%
-0.377
+10.92%
Estimates Revision
The market is revising Upward the revenue expectations for Recursion Pharmaceuticals, Inc. (RXRX) for FY2025, with the revenue forecasts being adjusted by 1.34% over the past three months. During the same period, the stock price has changed by -4.83%.
Revenue Estimates for FY2025
Revise Upward
+1.34%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+9.38%
In Past 3 Month
Stock Price
Go Down
-4.83%
In Past 3 Month
5 Analyst Rating
7.79% Upside
Wall Street analysts forecast RXRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RXRX is 5.95 USD with a low forecast of 3.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
4 Hold
0 Sell
Hold
7.79% Upside
Current: 5.520
Low
3.00
Averages
5.95
High
8.00
7.79% Upside
Current: 5.520
Low
3.00
Averages
5.95
High
8.00
Morgan Stanley
Equal Weight
initiated
$5
2025-07-03
Reason
Morgan Stanley
Price Target
$5
2025-07-03
initiated
Equal Weight
Reason
Morgan Stanley assumed coverage of Recursion Pharmaceuticals with an Equal Weight rating and $5 price target. Recursion has faced volatility due to a combination of macroeconomic factors, underperformance on initial clinical results and uncertainty on valuation and revenue drivers, the analyst tells investors in a research note. The recent pipeline prioritization and stage of clinical development for the proprietary pipeline leaves several open questions on valuation, the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
downgrade
$8 -> $5
2025-06-17
Reason
Morgan Stanley
Price Target
$8 -> $5
2025-06-17
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company's recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.
Morgan Stanley
Vikram Purohit
Hold
Maintains
$10 → $8
2025-04-10
Reason
Morgan Stanley
Vikram Purohit
Price Target
$10 → $8
2025-04-10
Maintains
Hold
Reason
Morgan Stanley lowered the firm's price target on Recursion Pharmaceuticals to $8 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model based on commentary through Q4 earnings and following the recent opportunity it had to catch-up with management on the current status of the pipeline, the analyst tells investors.
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-04-08
Reason
Needham
Gil Blum
Price Target
$11
2025-04-08
Reiterates
Strong Buy
Reason
Leerink Partners
Mani Foroohar
Hold
Maintains
$7 → $6
2025-02-28
Reason
Leerink Partners
Mani Foroohar
Price Target
$7 → $6
2025-02-28
Maintains
Hold
Reason
Needham
Gil Blum
Strong Buy
Reiterates
$11
2025-02-06
Reason
Needham
Gil Blum
Price Target
$11
2025-02-06
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Recursion Pharmaceuticals Inc (RXRX.O) is -3.96, compared to its 5-year average forward P/E of -7.55. For a more detailed relative valuation and DCF analysis to assess Recursion Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.55
Current PE
-3.96
Overvalued PE
-1.31
Undervalued PE
-13.79
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-6.53
Current EV/EBITDA
-3.15
Overvalued EV/EBITDA
0.86
Undervalued EV/EBITDA
-13.92
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
86.70
Current PS
5.52
Overvalued PS
226.10
Undervalued PS
-52.71
Financials
Annual
Quarterly
FY2025Q2
YoY :
+33.34%
19.22M
Total Revenue
FY2025Q2
YoY :
+75.28%
-176.23M
Operating Profit
FY2025Q2
YoY :
+76.23%
-171.90M
Net Income after Tax
FY2025Q2
YoY :
+2.50%
-0.41
EPS - Diluted
FY2025Q2
YoY :
-5.41%
-81.73M
Free Cash Flow
FY2025Q2
YoY :
-113.48%
-4.88
Gross Profit Margin - %
FY2025Q2
YoY :
-11.87%
-613.63
FCF Margin - %
FY2025Q2
YoY :
+32.17%
-894.23
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.1M
USD
4
3-6
Months
4.0M
USD
4
6-9
Months
1.1M
USD
3
0-12
Months
888.8K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
449.5K
Volume
1
0-12
Months
7.7M
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
3
24.9M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.1M
USD
4
3-6
Months
4.0M
USD
4
6-9
Months
1.1M
USD
3
0-12
Months
888.8K
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
RXRX News & Events
Events Timeline
2025-10-08 (ET)
2025-10-08
12:00:51
Recursion Pharmaceuticals Sees 17.9% Increase
2025-09-03 (ET)
2025-09-03
08:11:30
Rallybio Secures $12.5M Equity Milestone Payment from Recursion Pharmaceuticals
2025-08-18 (ET)
2025-08-18
08:45:02
Significant Borrowing Rate Hikes Among Liquid Assets
Sign Up For More Events
Sign Up For More Events
News
6.5
10-31NASDAQ.COMIs Recursion Pharmaceuticals Poised to Become a Major Player in AI Stocks?
2.0
10-28NASDAQ.COMRecursion Pharmaceuticals (RXRX) Shares Drop Despite Market Gains: Insights for Investors
9.5
10-28NewsfilterRecursion to Announce Third Quarter 2025 Business Updates and Financial Results on November 5th
Sign Up For More News
People Also Watch
CXW
CoreCivic Inc
18.530
USD
+1.15%
KLIC
Kulicke and Soffa Industries Inc
39.930
USD
+0.91%
PFS
Provident Financial Services Inc
18.290
USD
-1.08%
AIR
AAR Corp
84.210
USD
-0.01%
BNT
Brookfield Wealth Solutions Ltd
46.070
USD
+0.66%
RNW
Renew Energy Global PLC
7.540
USD
-0.53%
UE
Urban Edge Properties
19.230
USD
-0.62%
ELP
Companhia Paranaense de Energia
10.340
USD
+0.78%
ENR
Energizer Holdings Inc
23.230
USD
+0.13%
AIN
Albany International Corp
56.580
USD
-0.49%
FAQ
What is Recursion Pharmaceuticals Inc (RXRX) stock price today?
The current price of RXRX is 5.52 USD — it has decreased -2.3 % in the last trading day.
What is Recursion Pharmaceuticals Inc (RXRX)'s business?
What is the price predicton of RXRX Stock?
What is Recursion Pharmaceuticals Inc (RXRX)'s revenue for the last quarter?
What is Recursion Pharmaceuticals Inc (RXRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Recursion Pharmaceuticals Inc (RXRX)'s fundamentals?
How many employees does Recursion Pharmaceuticals Inc (RXRX). have?